Measuring human-error probabilities in drug preparation: a pilot simulation study.

Abstract:

OBJECTIVES:Designing a safe medication process requires the ability to model its reliability using methods such as probabilistic risk assessment (PRA). However, lack of data, especially on human-error probabilities (HEPs), limits its use. To assess whether small-scale simulations could help generate HEP data, a pilot study was conducted among nurses and anaesthetists. It focused on two core activities, namely, the manual preparation of medications and the arithmetic necessary to prepare drugs. Its specific objectives were to evaluate whether HEPs could be high enough to be measurable and to determine whether these HEPs could be sensitive to individuals and task details. These would give some insight into the level of detail required by PRA analysis. METHODS:Thirty nurse and 28 anaesthetist volunteers were involved in the experiment. Nurses and anaesthetists had to prepare medications for 20 patients and 22 syringes of various drugs, respectively. Both groups had to perform 22 calculations relating to the preparation of drugs. HEPs, distribution of HEPs and dependency of HEPs on individuals and task details were assessed. RESULTS:In the preparation tasks, overall HEP was 3.0% for nurses and 6.5% for anaesthetists. In the arithmetic tasks, overall HEP was 23.8% for nurses and 8.9% for anaesthetists. A statistically significant difference was noted between the two groups. In both preparation and arithmetic tasks, HEPs were dependent on individual nurses but not on individual anaesthetists. In every instance, HEPs were dependent on task details. CONCLUSION:Our study illustrates that small-scale simulations represent an interesting way of generating HEPs. HEPs are, indeed, in the range of 10(-2) and 10(-1). But in most cases, HEPs depend heavily on operators and task details. This dependency means that the influence of these parameters must be determined before advanced PRA analysis. There is therefore an urgent need to develop experimental research into assessing this influence by means of randomised controlled trials.

journal_name

Eur J Clin Pharmacol

authors

Garnerin P,Pellet-Meier B,Chopard P,Perneger T,Bonnabry P

doi

10.1007/s00228-007-0319-z

subject

Has Abstract

pub_date

2007-08-01 00:00:00

pages

769-76

issue

8

eissn

0031-6970

issn

1432-1041

journal_volume

63

pub_type

杂志文章
  • Pharmacokinetics and organ distribution of intravenous and oral methylene blue.

    abstract:OBJECTIVE:To determine the pharmacokinetics and organ distribution of i.v. and oral methylene blue, which is used to prevent ifosfamide-induced encephalopathy in oncology. METHODS:The concentration of methylene blue in whole blood was measured using high-performance liquid chromatography in seven volunteers after i.v....

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002280000124

    authors: Peter C,Hongwan D,Küpfer A,Lauterburg BH

    更新日期:2000-06-01 00:00:00

  • Clinical chronopharmacology of oral sustained-release isosorbide-5-mononitrate in healthy subjects.

    abstract::In 10 healthy male subjects the pharmacokinetics and haemodynamic effects of sustained-release isosorbide-5-mononitrate 60 mg (IS-5-MN) were studied after oral administration at two different times in the day (08.00 h and 20.00 h). Effects on blood pressure and heart rate after 3 min standing upright were measured in ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00315142

    authors: Lemmer B,Scheidel B,Blume H,Becker HJ

    更新日期:1991-01-01 00:00:00

  • Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients.

    abstract:OBJECTIVE:Iloprost is a potent PGI2 mimetic, which has been shown to be therapeutically effective in several vascular disorders. Due to its rapid clearance from the central compartment, iloprost is administered mainly by i.v. infusion, which limits its use to hospitalized patients. In order to improve pharmacotherapeut...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s002280050336

    authors: Hildebrand M

    更新日期:1997-01-01 00:00:00

  • A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers.

    abstract:PURPOSE:Ticagrelor is a reversibly binding P2Y12 receptor antagonist for the prevention of atherothrombotic events in patients with acute coronary syndrome. Previous in vitro studies showed that ticagrelor is a substrate and inhibitor of P-glycoprotein (ABCB1). Therefore, we examined the potential interaction between d...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00228-013-1543-3

    authors: Teng R,Butler K

    更新日期:2013-10-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years.

    abstract:OBJECTIVE:To investigate (1) the pharmacokinetic and pharmacodynamic profiles of desmopressin in men from an age group with a high incidence of nocturia; and (2) circadian variation in the pharmacokinetic parameters. METHODS:The study had an open, randomised, four-way cross-over design. Desmopressin was administered o...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/s00228-004-0781-9

    authors: Rembratt A,Graugaard-Jensen C,Senderovitz T,Norgaard JP,Djurhuus JC

    更新日期:2004-08-01 00:00:00

  • Pharmacokinetics of ethanol in plasma and whole blood: estimation of total body water by the dilution principle.

    abstract::The pharmacokinetics of ethanol in plasma and whole blood have been investigated and the results used to estimate the volume of total body water (TBW) by means of the dilution principle. Fifteen men (mean age 62 y) were given 0.6 g ethanol/kg body weight as an intravenous infusion over 1 h. The peak concentration of e...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00280133

    authors: Jones AW,Hahn RG,Stalberg HP

    更新日期:1992-01-01 00:00:00

  • The influence of cimetidine versus ranitidine on doxepin pharmacokinetics.

    abstract::The effect of cimetidine and ranitidine on doxepin pharmacokinetics was studied in 6 healthy volunteers. Each subject completed 3 study phases: Treatment A, 9 consecutive doses of 50 mg doxepin (once daily); Treatment B, same as Treatment A but co-administration of cimetidine 600 mg b.i.d. starting after the sixth dox...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00542189

    authors: Sutherland DL,Remillard AJ,Haight KR,Brown MA,Old L

    更新日期:1987-01-01 00:00:00

  • Pharmacokinetics of theophylline in hyperthyroid and hypothyroid patients with chronic obstructive pulmonary disease.

    abstract::The pharmacokinetics of theophylline was investigated in five hyperthyroid, five hypothyroid, and five euthyroid patients, all with chronic obstructive pulmonary disease. Wide individual variability was found in theophylline kinetics, but the rate of elimination of theophylline was significantly higher in hyperthyroid...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00544240

    authors: Pokrajac M,Simić D,Varagić VM

    更新日期:1987-01-01 00:00:00

  • Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans.

    abstract:PURPOSE:Tamsulosin is one of the most potent drugs currently available to treat benign prostatic hyperplasia. Cytochrome P450 (CYP) 2D6 and CYP3A are the two major enzymes responsible for tamsulosin metabolism. The purpose of this study was to evaluate the effects of CYP2D6 and CYP3A5 genetic polymorphisms on the pharm...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-018-2501-x

    authors: Kim KA,Park IB,Park JY

    更新日期:2018-10-01 00:00:00

  • Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.

    abstract:PURPOSE:The population pharmacokinetics (PK) of lopinavir in tuberculosis (TB)/human immunodeficiency virus (HIV) co-infected South African children taking super-boosted lopinavir (lopinavir/ritonavir ratio 1:1) as part of antiretroviral treatment in the presence of rifampicin were compared with the population PK of lo...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-010-0847-9

    authors: Elsherbiny D,Ren Y,McIlleron H,Maartens G,Simonsson US

    更新日期:2010-10-01 00:00:00

  • Effect of procainamide on left ventricular performance in patients with primary myocardial disease.

    abstract::The effect of procainamide (P) on left ventricular function as measured by the systolic time intervals (STI) was studied in 14 patients with primary myocardial disease. P, 7.5 mg/kg body weight, was given intravenously at a rate of 100 mg per minute. Administration of P produced a decrease in left ventricular performa...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00561387

    authors: Geleris P,Boudoulas H,Schaal SF,Lewis RP,Lima JJ

    更新日期:1980-10-01 00:00:00

  • Stereoselective handling of perhexiline: implications regarding accumulation within the human myocardium.

    abstract:PURPOSE:Perhexiline is a prophylactic anti-ischaemic agent with weak calcium antagonist effect which has been increasingly utilised in the management of refractory angina. The metabolic clearance of perhexiline is modulated by CYP2D6 metaboliser status and stereoselectivity. The current study sought to (1) determine wh...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00228-015-1934-8

    authors: Chong CR,Drury NE,Licari G,Frenneaux MP,Horowitz JD,Pagano D,Sallustio BC

    更新日期:2015-12-01 00:00:00

  • Efficacy, safety and cost of new cardiovascular drugs: a survey.

    abstract::To assess the type and degree of innovation of the cardiovascular drugs centrally approved in the European Union between 1995 and 2002. Sources of information were the European Public Assessment Reports and the Summaries of Product Characteristics published by the European Medicines Evaluation Agency. The Agency appro...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-003-0634-y

    authors: Garattini S,Bertele' V

    更新日期:2003-11-01 00:00:00

  • Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications.

    abstract:PURPOSE:Drug utilization studies have applied different methods to various data types to describe medication use, which hampers comparisons across populations. The aim of this study was to describe the time trends in antidepressant prescribing in the last decade and the variation in the prevalence, calculated in a unif...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00228-014-1676-z

    authors: Abbing-Karahagopian V,Huerta C,Souverein PC,de Abajo F,Leufkens HG,Slattery J,Alvarez Y,Miret M,Gil M,Oliva B,Hesse U,Requena G,de Vries F,Rottenkolber M,Schmiedl S,Reynolds R,Schlienger RG,de Groot MC,Klungel OH,va

    更新日期:2014-07-01 00:00:00

  • Hyperforin in St. John's wort drug interactions.

    abstract::Recently, interactions of herbal medicines with synthetic drugs came into focus of particular interest. In the past 3 years, more than 50 papers were published regarding interactions between St. John's wort (Hypericum perforatum L.; SJW) and prescription drugs. Co-medication with SJW resulted in decreased plasma conce...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/s00228-006-0096-0

    authors: Madabushi R,Frank B,Drewelow B,Derendorf H,Butterweck V

    更新日期:2006-03-01 00:00:00

  • Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region.

    abstract:PURPOSE:This study evaluated the benefits of and possible contraindications to warfarin treatment in patients with atrial fibrillation (AF) prior to the introduction of new oral anticoagulants using health registry data from inpatient care, specialist ambulatory care, and primary care. METHODS:This is a cohort study i...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-014-1739-1

    authors: Forslund T,Wettermark B,Wändell P,von Euler M,Hasselström J,Hjemdahl P

    更新日期:2014-12-01 00:00:00

  • Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients.

    abstract:PURPOSE:The pharmacokinetics of orally administered immediate-release, twice-daily (BID) and modified-release, once-daily (QD) formulations of tacrolimus have high interindividual variability. We investigated factors affecting interindividual variability of tacrolimus bioavailability in renal transplant patients. METH...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00228-013-1514-8

    authors: Niioka T,Kagaya H,Miura M,Numakura K,Saito M,Inoue T,Habuchi T,Satoh S

    更新日期:2013-09-01 00:00:00

  • Pharmacokinetics of metoprolol in healthy, elderly, non-smoking individuals after a single dose and two weeks of treatment.

    abstract::The effect of long-term treatment on the absorption and disposition of metoprolol has been evaluated in 8 healthy, non-smoking, elderly individuals (mean age 74.5 years) and in a control group of 8 healthy, young individuals. Two trace doses of [3H]metoprolol were given i.v., first concomitantly with a single oral 50 ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00544048

    authors: Larsson M,Landahl S,Lundborg P,Regårdh CG

    更新日期:1984-01-01 00:00:00

  • Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.

    abstract::The pharmacokinetics and metabolism of quinidine were investigated in extensive and poor metabolisers of sparteine. No differences in plasma clearance, terminal half life, volume of distribution or cumulative urinary excretion of quinidine, 3-hydroxyquinidine and quinidine-N-oxide were observed between phenotypes. Thu...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00870989

    authors: Mikus G,Ha HR,Vozeh S,Zekorn C,Follath F,Eichelbaum M

    更新日期:1986-01-01 00:00:00

  • Effect of carbamazepine on psychomotor performance in näive subjects.

    abstract::The effect of a single dose of carbamazepine (CBZ), 10 mg kg-1, on a battery of simple psychomotor tests was investigated in 12 healthy subjects (6 male, 6 female) in a balanced randomised double blind placebo controlled cross-over study. Psychomotor testing and blood sampling for total and free plasma CBZ, and CBZ 10...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00614193

    authors: MacPhee GJ,Goldie C,Roulston D,Potter L,Agnew E,Laidlaw J,Brodie MJ

    更新日期:1986-01-01 00:00:00

  • Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients.

    abstract::The effect of dexfenfluramine (dF) on body weight, blood pressure and noradrenergic activity were studied in 30 obese hypertensive patients randomly divided into two groups and treated for 3 months either with dF (30 mg daily; 16 subjects) or placebo (Pl; 14 subjects). 11 patients from the dF group and 9 patients give...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00265922

    authors: Kolanowski J,Younis LT,Vanbutsele R,Detry JM

    更新日期:1992-01-01 00:00:00

  • Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide.

    abstract:OBJECTIVE:To investigate the potential for pharmacokinetic interactions between moexipril, a new converting enzyme inhibitor, and hydrochlorothiazide after single dose administration. METHODS:12 healthy male volunteers were studied by an open, randomised, three-way cross-over design, in which single doses of moexipril...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/s002280050209

    authors: Hutt V,Michaelis K,Verbesselt R,De Schepper PJ,Salomon P,Bonn R,Cawello W,Angehrn JC

    更新日期:1996-01-01 00:00:00

  • Bilateral surgical removal of impacted lower third molar teeth as a model for drug evaluation: a test with ibuprofen.

    abstract::It was considered that double-blind crossover studies of therapeutic efficacy after acute injury could well be done in patients who required surgical removal of impacted wisdom teeth from both sides of the lower jaw. In the present trial 24 healthy patients received either placebo or ibuprofen (Brufen: 400 mg three ti...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00567117

    authors: Lökken P,Olsen I,Bruaset I,Norman-Pedersen K

    更新日期:1975-04-04 00:00:00

  • The influence of haemodialysis and haemofiltration on the clearance of torasemide in renal failure.

    abstract::The concentration of Torasemide in plasma, dialysate and ultrafiltrate were determined during one haemofiltration and three dialyses. Results show that Torasemide is not significantly eliminated from the blood by these technics. ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00541468

    authors: Loute G,Adam A,Ers P,Heremans C,Willems B

    更新日期:1986-01-01 00:00:00

  • Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.

    abstract:PURPOSE:Pre-clinical experiments have shown that almorexant, a dual orexin receptor antagonist, is able to inhibit cytochrome P450 3A4 (CYP3A4). Therefore, a study was conducted to investigate the effects of multiple-dose almorexant on the pharmacokinetics of midazolam and simvastatin, two CYP3A4 model substrates. MET...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00228-012-1403-6

    authors: Hoch M,Hoever P,Alessi F,Theodor R,Dingemanse J

    更新日期:2013-03-01 00:00:00

  • Plasma timolol levels after oral and intravenous administration.

    abstract::The plasma kinetics of timolol administered orally and intravenously to 5 male subjects were examined. Bioavailability was reduced by 25% when the drug was taken orally. Mean plasma half-life after oral dosing was 4.86 h, and after intravenous administration it was 4.56 h; the difference was not significant. The volum...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00716385

    authors: Else OF,Sorenson H,Edwards IR

    更新日期:1978-12-18 00:00:00

  • Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy.

    abstract:BACKGROUNDS AND AIMS:Development of safe and effective rescue regimens for eradication failure of Helicobacter pylori infection by standard regimens is an urgent task. We designed the prospective study to compare the efficacy of two rescue regimens after eradication failure by the standard triple therapy. METHODS:One ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00228-007-0302-8

    authors: Shirai N,Sugimoto M,Kodaira C,Nishino M,Ikuma M,Kajimura M,Ohashi K,Ishizaki T,Hishida A,Furuta T

    更新日期:2007-08-01 00:00:00

  • Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers.

    abstract:PURPOSE:As an inhibitor of HMG-CoA reductase that catalyses the first step of cholesterol synthesis, pitavastatin undergoes little hepatic metabolism; however, it is a substrate of uptake and efflux transporters. Since pitavastatin is potentially co-administered with agents that affect transporter activities, the pharm...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00228-013-1554-0

    authors: Chen Y,Zhang W,Huang WH,Tan ZR,Wang YC,Huang X,Zhou HH

    更新日期:2013-11-01 00:00:00

  • Paracetamol test: modification by renal function, urine flow and pH.

    abstract::Factors which might affect paracetamol disposition have been studied in a heterogenous group of patients in need of mild analgesia in an intensive care unit. Following oral administration of 1 g of paracetamol, plasma and urinary concentrations of the parent compound and metabolites were assessed by HPLC. The renal cl...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00315104

    authors: Kietzmann D,Bock KW,Krähmer B,Kettler D,Bircher J

    更新日期:1990-01-01 00:00:00

  • Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays.

    abstract:OBJECTIVES:To compare the systemic exposure for intranasal mometasone furoate (MF) and fluticasone propionate (FP) aqueous nasal sprays (ANS) in terms of serum and urinary cortisol parameters and plasma pharmacokinetics. METHODS:Twelve healthy subjects completed this three-way, cross-over study. They received FPANS (5...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/s00228-004-0763-y

    authors: Daley-Yates PT,Kunka RL,Yin Y,Andrews SM,Callejas S,Ng C

    更新日期:2004-06-01 00:00:00